RxDoctor Payments Data

Carrie Kramer

Psychiatric/Mental Health · Syracuse, NYNPI 1881389328

Payments from drug & device makers

$4,674in general payments, 2019–2025

Across 253 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Teva Pharmaceuticals USA, Inc.$837
  • AbbVie$542
  • Alkermes, Inc.$383
  • Otsuka America Pharmaceutical, Inc.$341
  • Lundbeck LLC$290
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$4,61999%
  • Education$551%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,674 in reported general payments places this provider in the 90th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$14,035
Medicare patients
22
Services billed
177

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole21$61,911
VraylarCariprazine Hcl16$24,381
Lisdexamfetamine Dimesylate11$2,839
Lurasidone Hcl18$2,271
Trazodone Hcl59$1,050
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine12$947
Duloxetine Hcl46$801
Aripiprazole50$795
Lamotrigine ErLamotrigine13$784
Atomoxetine Hcl11$767
Quetiapine Fumarate20$703
Alprazolam51$477
Fluoxetine Hcl16$294
Bupropion Hcl SrBupropion Hcl12$288
Modafinil12$253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$341$61,91121 claims
AbbVieVraylar$542$24,38116 claims
Almatica Pharma LLCSertraline Hcl$18$11521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →